Navigation Links
Meningitis vaccine study gets £200,000 boost
Date:2/7/2008

It can kill in four hours and more than 300 people in the UK die from it every year and hundreds more are left with permanent disabilities. Now researchers will work on a potential vaccine for meningitis B, thanks to a 200,000 grant from the medical charity Meningitis UK.

Although vaccines exist to protect against some strains of meningitis, there is still no vaccine to protect against all strains, including the most common in the UK Group B meningococci. This is responsible for almost 90 per cent of all cases and is most common in children under the age of five.

The team, led by Dr Karl Wooldridge, a lecturer in the Centre for Biomolecular Sciences, aim to develop a vaccine against this strain of the bacterium. Group B meningococci mimic molecules in the human body, which makes developing an effective vaccine against this strain very difficult.

Researchers worldwide are searching for alternative antigens molecules that can stimulate an immune response on the surface of the bacteria, which could be used as a basis for a vaccine against meningitis B.

The team has identified a series of autotransporter proteins proteins which are secreted from the surface of Group B meningococci which could be used to create antibodies that will then kill the bacteria.

The grant will be used to fund a two-year research post, examining each of the proteins produced by the bacteria for the potential to create effective antibodies. The genetic code for each protein will be cloned and tagged, allowing the protein to be produced in large amounts and purified for further study.

If we identify one or more of these proteins that give a good protective response we would ultimately move to human trials, said Dr Wooldridge. This would hopefully demonstrate a positive immune response to the vaccine. By identifying a range of active proteins, rather than just one, we could develop a vaccine that targeted all strains of the Group B meningococci.

Meningitis UK launched its Search 4 a Vaccine Campaign in 2007 to help raise 7million over the next seven years to fund vital work into developing a vaccine against Group B. This innovative project is just one of the studies the charity is funding.

Meningitis UKs Chief Executive Steve Dayman said: We are extremely pleased to be funding Dr Karl Wooldridge and his team in their work to discover more about the proteins secreted by the Meningitis B bacteria. If this research can go forward to help develop a vaccine, thousands of lives could be saved.

Meningitis can be incredibly hard to detect as many of its symptoms are often similar to more minor ailments such as the common cold or flu, plus there are occasions when people show no, or very few, symptoms. For these reasons, we believe the only way to eradicate meningitis completely is through the development of a preventative vaccine.


'/>"/>

Contact: Karl Wooldridge
karl.wooldridge@nottingham.ac.uk
University of Nottingham
Source:Eurekalert

Related medicine news :

1. Schedules Revised for Flu, Meningitis Vaccines
2. New Meningitis Vaccine Works in Infants
3. Steroid Fails to Ease Meningitis in Trials
4. Meningitis Shot Available, Effective Year-Round
5. Tattooing Best Way to Deliver DNA Vaccines
6. Novel molecules developed at UB can boost vaccine potency
7. USDA Agrees to Grant Conditional License to Bioniche for its E. coli O157:H7 Cattle Vaccine
8. Another Study Finds No Link Between MMR Vaccine and Autism
9. New hospital standards needed for pediatric flu vaccines
10. Experimental Vaccine Halts Prostate Cancer in Mice
11. Novel vaccine concept developed by scientists at the Wistar Institute
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... October 13, 2017 , ... ProVest Insurance Group, a family ... and Raleigh regions, is organizing an extended charity drive to benefit the family ... abnormality. , After struggling since birth with several health challenges, T.J. was later ...
(Date:10/13/2017)... ... October 13, 2017 , ... The ... to promote standards of excellence for the field of eating disorders, announces the ... – 25, 2018 in Orlando, Florida at the Omni Resort at ChampionsGate. ...
(Date:10/13/2017)... LUIS OBISPO, Calif. (PRWEB) , ... October 13, 2017 , ... ... Alzheimer’s or dementia. However, many long-term care insurance companies have a waiver for care ... is the 90-day elimination period, when the family pays for care, is often waived, ...
(Date:10/13/2017)... ... October 13, 2017 , ... Talented host, actor Rob Lowe, ... in a new episode of "Success Files," which is an award-winning educational program ... investigates each subject in-depth with passion and integrity. , Sciatica occurs when the ...
(Date:10/12/2017)... ... October 12, 2017 , ... CitiDent and San ... using cutting-edge Oventus O2Vent technology. As many as 18 million Americans are ... cessation in breathing. Oral appliances can offer significant relief to about 75 percent ...
Breaking Medicine News(10 mins):
(Date:10/2/2017)... Halo Labs announces the European launch of their new low volume, ... 2017 in Cambridge, U.K on October 4th. ... samples with unprecedented speed and sensitivity while using far less sample ... ... system ...
(Date:9/27/2017)... , Sept. 27, 2017  Commended for their devotion ... notable awards. Ranked as number one in the South Florida ... time in Inc. 5000 yearly list, the national specialty pharmacy ... Armando Bardisa will soon be honored by SFBJ ... Set to receive his award in ...
(Date:9/23/2017)... Pa. , Sept. 22, 2017 Janssen ... a complete response letter from the U.S. Food and ... seeking approval of sirukumab for the treatment of moderately ... letter indicates additional clinical data are needed to further ... moderately to severely active RA. ...
Breaking Medicine Technology: